Human autologous T cells do not engraft in immunocompetent animals; no representative models
“Ide-cel comprises engineered human T cells, therefore there are no representative in vitro assays, ex vivo models, or in vivo models that can accurately address the toxicological characteristics of the human product.”
No surrogate; human ide-cel tested in NSG mice with human MM xenografts
“Rapid elimination of both subcutaneous and systemic tumours and increased survival was demonstrated in NSG mice with BCMA+ xenografts after a single dose of ide-cel.”
None; no repeat-dose toxicity studies (human T cells do not engraft in immunocompetent animals)
“No single or repeat-dose toxicity studies were conducted with ide-cel as traditional animal studies employing common toxicology study designs are not appropriate for ide-cel since autologous human T cells do not graft in immunocompetent animals.”
“No animal reproductive and developmental toxicity studies were conducted for bb2121 which is acceptable based on the product characteristics.”
✓ VerifiedFDA pharmacology/toxicology review, p. 2Source ↗
Species: carcinogenicity
Not conducted; in vitro IL-2-independent growth assay instead
“No carcinogenicity or tumorigenicity studies were conducted for bb2121. However, the applicant evaluated IL-2 independent growth in Study #10.”
✓ VerifiedFDA pharmacology/toxicology review, p. 27Source ↗
Surrogate used in
No surrogate used; clinical ide-cel tested in NSG mice with BCMA+ xenografts
“Rapid elimination of both subcutaneous and systemic tumours and increased survival was demonstrated in NSG mice with BCMA+ xenografts after a single dose of ide-cel.”